NCT00920868View on ClinicalTrials.gov

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

August 31, 2014

Conditions
Solid TumorMetastatic Colorectal Cancer
Interventions
DRUG

dasatinib

dasatinib at 50 mg PO BID)

DRUG

bevacizumab

7.5 mg/kg IV day 1

DRUG

Oxaliplatin

130 mg/m2 IV day 1

DRUG

Capecitabine

850 mg/m2 PO BID on days 1-14

Trial Locations (2)

27710

Duke Univeristy Medical Center, Durham

80218

Rocky Mountain Cancer Center, Denver

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Herbert Hurwitz, MD

OTHER

NCT00920868 - XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | Biotech Hunter | Biotech Hunter